Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer

INTRODUCTION: Immunochemotherapy using PD-1/PD-L1 antibodies in combination with chemotherapeutic agents has become a mainstream treatment for cancer patients, but it remains unclear which drug combinations would produce best therapeutic outcome. OBJECTIVES: The purpose of this study was to investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Glorieux, Christophe, Xia, Xiaojun, You, Xin, Wang, Zining, Han, Yi, Yang, Jing, Noppe, Gauthier, Meester, Christophe de, Ling, Jianhua, Robert, Annie, Zhang, Hui, Li, Sheng-Ping, Wang, Huamin, Chiao, Paul J., Zhang, Li, Li, Xiaobing, Huang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481954/
https://www.ncbi.nlm.nih.gov/pubmed/36100320
http://dx.doi.org/10.1016/j.jare.2021.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481954/
https://www.ncbi.nlm.nih.gov/pubmed/36100320
http://dx.doi.org/10.1016/j.jare.2021.12.005

Ejemplares similares